129 related articles for article (PubMed ID: 21574421)
1. [Lack of levofloxacin and moxyfloxacin efficacy in experimental plague of albino mice infected with nalidixic acid resistant pathogen (Nal(r))].
Ryzhko IV; Trishina AV; Verkina LM
Antibiot Khimioter; 2010; 55(11-12):22-4. PubMed ID: 21574421
[TBL] [Abstract][Full Text] [Related]
2. [Efficacy of levofloxacin, lomefloxacin and moxifloxacin vs. other fluoroquinolones in experimental plague due to FI+ and FI- strains of Yersinia pestis in Albino mice].
Ryzhko IV; Tsuraeva RI; Anisimov BI; Trishina AV
Antibiot Khimioter; 2009; 54(5-6):37-40. PubMed ID: 20052916
[TBL] [Abstract][Full Text] [Related]
3. [Formation of virulent antigen-modified mutants (Fra-, Fra-Tox-) of plague bacteria resistant to rifampicin and quinolones].
Ryzhko IV; Shcherbaniuk AI; Skalyga EIu; Tsuraeva RI; Moldavan IA
Antibiot Khimioter; 2003; 48(4):19-23. PubMed ID: 13677133
[TBL] [Abstract][Full Text] [Related]
4. [Ofloxacin efficacy in the prophylaxis and treatment of experimental plague due to antigen complete and defective strains of the pathogen].
Samokhodkina ED; Shcherbaniuk AI; Ryzhko IV; Tsuraeva RI; Skalyga EIu
Antibiot Khimioter; 2002; 47(3):26-9. PubMed ID: 16127904
[TBL] [Abstract][Full Text] [Related]
5. Impact of resistance selection and mutant growth fitness on the relative efficacies of streptomycin and levofloxacin for plague therapy.
Louie A; Deziel MR; Liu W; Drusano GL
Antimicrob Agents Chemother; 2007 Aug; 51(8):2661-7. PubMed ID: 17517837
[TBL] [Abstract][Full Text] [Related]
6. Braun lipoprotein (Lpp) contributes to virulence of yersiniae: potential role of Lpp in inducing bubonic and pneumonic plague.
Sha J; Agar SL; Baze WB; Olano JP; Fadl AA; Erova TE; Wang S; Foltz SM; Suarez G; Motin VL; Chauhan S; Klimpel GR; Peterson JW; Chopra AK
Infect Immun; 2008 Apr; 76(4):1390-409. PubMed ID: 18227160
[TBL] [Abstract][Full Text] [Related]
7. [Virulence of rifampicin and quinolone resistant mutants of strains of plague microbe with Fra+ and Fra- phenotypes].
Ryzhko IV; Shcherbaniuk AI; Samokhodkina ED; Tsuraeva RI; Mishn'kin BN; Kasatkina IV; Zhigalova TA
Antibiot Khimioter; 1994 Apr; 39(4):32-6. PubMed ID: 7826172
[TBL] [Abstract][Full Text] [Related]
8. Cethromycin-mediated protection against the plague pathogen Yersinia pestis in a rat model of infection and comparison with levofloxacin.
Rosenzweig JA; Brackman SM; Kirtley ML; Sha J; Erova TE; Yeager LA; Peterson JW; Xu ZQ; Chopra AK
Antimicrob Agents Chemother; 2011 Nov; 55(11):5034-42. PubMed ID: 21859946
[TBL] [Abstract][Full Text] [Related]
9. [Chromosomal resistance of plague agent to quinolones].
Kasatkina IV; Shcherbaniuk AI; Makarovskaia LN; Padeĭskaia EN
Antibiot Khimioter; 1991 Aug; 36(8):35-7. PubMed ID: 1661573
[TBL] [Abstract][Full Text] [Related]
10. [Isepamycin in prophylaxis and treatment of experimental plague due to FI+ and FI- variants of plague microbe].
Smorodinova IuV; Shcherbaniuk AI; Ryzhko IV; Moldavan IA
Antibiot Khimioter; 2005; 50(8-9):23-6. PubMed ID: 17016907
[TBL] [Abstract][Full Text] [Related]
11. [Synergistic action of some antibacterial agents in studies on albino mice with experimental plague caused by Fr- phenotype strain of the plague microbe].
Shcherbaniuk AI; Liukshina EIu; Ryzhko IV; Smorodinova IuV
Antibiot Khimioter; 2006; 51(1):7-10. PubMed ID: 16734358
[TBL] [Abstract][Full Text] [Related]
12. [Effectiveness of new quinolones in experimental aerogenic plague infection of albino mice].
Shcherbaniuk AI; Lozovoĭ NV; Kasatkina IV; Pasiukov VV
Antibiot Khimioter; 1994 Jun; 39(6):13-4. PubMed ID: 7847999
[TBL] [Abstract][Full Text] [Related]
13. [A comparative study of fluoroquinolones and 3rd-generation cephalosporins in the prevention and treatment of experimental plague caused by Yersinia pestis strains typical and serologically atypical with respect to F1].
Ryzhko IV; Shcherbaniuk AI; Tsuraeva RI; Samokhodkina ED; Kasatkina IV; Tsetskhladze NS; Pasiukov VV; Roshchina NV
Antibiot Khimioter; 1997; 42(1):12-6. PubMed ID: 9221699
[TBL] [Abstract][Full Text] [Related]
14. In vitro activities of 14 antibiotics against 100 human isolates of Yersinia pestis from a southern African plague focus.
Frean JA; Arntzen L; Capper T; Bryskier A; Klugman KP
Antimicrob Agents Chemother; 1996 Nov; 40(11):2646-7. PubMed ID: 8913481
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of the latest fluoroquinolones against experimental Yersinia pestis.
Steward J; Lever MS; Russell P; Beedham RJ; Stagg AJ; Taylor RR; Brooks TJ
Int J Antimicrob Agents; 2004 Dec; 24(6):609-12. PubMed ID: 15555886
[TBL] [Abstract][Full Text] [Related]
16. [The experimental validation of the advantages of combined emergency (fluoroquinolones) and specific (EV Nalr) prevention of plague versus their sequential use].
Ryzhko IV; Tsuraeva RI; Samokhodkina ED; Shcherbaniuk AI; Mishan'kin BN; Koroleva NS; Anisimov BN
Antibiot Khimioter; 2000; 45(7):10-3. PubMed ID: 10987101
[TBL] [Abstract][Full Text] [Related]
17. Doxycycline or ciprofloxacin prophylaxis and therapy against experimental Yersinia pestis infection in mice.
Russell P; Eley SM; Bell DL; Manchee RJ; Titball RW
J Antimicrob Chemother; 1996 Apr; 37(4):769-74. PubMed ID: 8722542
[TBL] [Abstract][Full Text] [Related]
18. Comparison of 2 antibiotics that inhibit protein synthesis for the treatment of infection with Yersinia pestis delivered by aerosol in a mouse model of pneumonic plague.
Heine HS; Louie A; Sorgel F; Bassett J; Miller L; Sullivan LJ; Kinzig-Schippers M; Drusano GL
J Infect Dis; 2007 Sep; 196(5):782-7. PubMed ID: 17674322
[TBL] [Abstract][Full Text] [Related]
19. [Evaluation of the effectiveness of antibacterial substances in treating an experimental form of bubonic plague in monkeys].
Romanov VE; Evstigneev VI; Vasil'ev NT; Shabalin BA; Paramonov VE
Antibiot Khimioter; 2001; 46(8):6-8. PubMed ID: 11871319
[TBL] [Abstract][Full Text] [Related]
20. Fluoroquinolone resistance of Pseudomonas aeruginosa isolates causing nosocomial infection is correlated with levofloxacin but not ciprofloxacin use.
Lee YJ; Liu HY; Lin YC; Sun KL; Chun CL; Hsueh PR
Int J Antimicrob Agents; 2010 Mar; 35(3):261-4. PubMed ID: 20045290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
